Lexaria Bioscience Reports AUD 3.67M Australian R&D Tax Credit

What Happened
Lexaria Bioscience Corp. (LEXX) filed a Form 8-K (Item 8.01) reporting that its wholly owned subsidiary, Lexaria (AU) Pty Ltd, received an Australian Research & Development (R&D) tax incentive credit of AUD$3,666,611.98 (USD$2.6M) on August 28, 2026. The subsidiary holds the exclusive rights to use Lexaria’s DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in Australia. The credit was deposited into the subsidiary’s Australian bank account to pursue additional research and development opportunities in Australia.

Key Details

• Received amount: AUD$3,666,611.98 (approximately USD$2.6M).
• Date received: August 28, 2026.
• Recipient: Lexaria (AU) Pty Ltd, a wholly owned subsidiary of Lexaria Bioscience.
• Intended use: Funds deposited locally for additional R&D activities related to DehydraTECH in Australia.

Why It Matters
This cash receipt reduces near-term funding pressure for Lexaria’s Australian clinical and R&D programs by adding about USD$2.6M to the subsidiary’s local resources. For investors, it is a non-operating, one-time tax incentive payment (not revenue) that supports continued development of DehydraTECH-enabled pharmaceutical programs in Australia and may help advance ongoing clinical work without immediate additional capital from the parent company.